Eli Lilly and Company (LLY)vsSpero Therapeutics Inc (SPRO)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
SPRO
Spero Therapeutics Inc
$2.51
-0.79%
HEALTHCARE · Cap: $154.60M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 97470% more annual revenue ($65.18B vs $66.80M). LLY leads profitability with a 31.7% profit margin vs 12.8%. SPRO trades at a lower P/E of 17.8x. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SPRO
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+51.9%
Fair Value
$4.95
Current Price
$2.51
$2.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Strong operational efficiency at 76.0%
Revenue surging 174.5% year-over-year
Earnings expanding 75.3% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : SPRO
The strongest argument for SPRO centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 174.5% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : SPRO
The primary concerns for SPRO are Market Cap, Free Cash Flow.
Key Dynamics to Monitor
SPRO carries more volatility with a beta of 1.45 — expect wider price swings.
SPRO is growing revenue faster at 174.5% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 63/100), backed by strong 31.7% margins and 42.6% revenue growth. SPRO offers better value entry with a 51.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Spero Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR) bacterial infections and rare diseases in the United States. The company is headquartered in Cambridge, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?